Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Palatin (PTN) fell $0.67 (61%) to $1.06 on Thursday after it and partner King (KG) said the
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury